Savara Inc. (SVRA) - Q1 2025 10-Q Summary
Business Context and Reporting Period
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its sole program is MOLBREEVI (molgramostim inhalation solution), an investigational inhaled biologic in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). The company has no product revenue to date and operates as a single segment. This report covers the quarterly period ended March 31, 2025.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(26.6) million | $(20.3) million |
| Net Loss Per Share (Basic/Diluted) | $(0.12) | $(0.11) |
| Operating Expenses | $28.4 million | $22.5 million |
| Cash & Cash Equivalents | $19.6 million | $16.8 million |
| Short-term Investments | $152.9 million | $181.2 million |
| Total Liquidity | $172.5 million | $198.0 million |
| Long-term Debt | $29.5 million | $26.6 million |
| Cash Used in Operating Activities | $(27.2) million | $(20.6) million |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by $6.3 million (31%) compared to Q1 2024, driven by higher operating expenses.
- Expense Growth:
- R&D Expenses: Increased by $2.4 million (14%) to $19.2 million, primarily due to regulatory affairs and quality assurance costs for the MOLBREEVI program.
- G&A Expenses: Increased by $3.6 million (64%) to $9.2 million, driven by personnel costs and commercial preparation activities.
- Debt Restructuring: The company entered a new $200 million credit facility with Hercules Capital on March 26, 2025. The initial $30 million tranche was used to repay the prior Silicon Valley Bank loan, resulting in a $0.5 million loss on extinguishment of debt.
- Investment Portfolio: Short-term investments decreased by $28.3 million due to maturities and purchases, though net cash from investing activities was positive ($29.3 million) due to significant maturities.
Outlook, Risks, and Management Commentary
- Regulatory Milestone: Savara completed the submission of the Biological License Application (BLA) to the FDA for MOLBREEVI in March 2025, following positive top-line results from the Phase 3 IMPALA-2 trial.
- Capital Resources: Management states that current cash and short-term investments ($172.5 million) are sufficient to fund operations for at least the next 12 months. However, additional capital may be required for commercialization.
- Debt Covenants: The new Hercules Loan Agreement includes restrictive covenants, including a "Cash Requirement" (maintaining 50% of outstanding principal in unrestricted cash) and a "Conditional Minimum Revenue Covenant" tied to future sales performance. Failure to meet these could trigger default.
- ATM Termination: The company terminated its "at-the-market" (ATM) equity sales agreement with Evercore, effective April 2, 2025.
- Risks: Key risks include the uncertainty of FDA approval, the ability to raise additional capital on favorable terms, and compliance with the new debt covenants.
Investor Verification Checklist
- BLA Review Timeline: Verify the FDA's acceptance of the BLA and the expected timeline for a decision.
- Debt Covenant Compliance: Monitor the company's ability to maintain the 50% cash reserve requirement under the Hercules Loan Agreement.
- Burn Rate: Track quarterly cash usage to confirm the 12-month runway estimate remains valid as commercialization costs potentially rise.
- Manufacturing Commitments: Review the $801,000 in disclosed contingent milestone payments and the $28 million commitment to the second-source API manufacturer.
- Equity Dilution: Assess the impact of outstanding warrants (approx. 43.7 million shares) and options (approx. 13.1 million shares) on future share count.